MID Bank launches new brand in Egyptian market    Emaar Misr records one of Egypt's highest real estate sales figures in 2020    Egypt's Senate elects heads, members of special committees    Egypt‘s Shoukry, Greek counterpart discuss bilateral cooperation, regional issues    400k Egyptians registered for COVID-19 vaccines: Health Minister    Women comprise 42% of Careem Egypt employees    Aboul Gheit, UN representative discuss boosting political process in Libya    AlTameer Arabian's Rivan Tower sells out in 2 hours    Egypt, France conduct joint military exercises in Red Sea    Egypt set to launch new export support programme in July    Celebrating International Women's Day, Misr Insurance Takaful offers special discounts on four policies    Every place contains certain energy that affects visitor: Photographer Romany Hafez    3rd Rashid Bin Hamad Al Sharqi Award opens registrations    Berlinale Golden Bear award goes to Radu Jude's ‘Bad Luck Banging'    Misr Italia launches The Cliff, The Park phases in IL BOSCO    Egypt emphasises enhanced cooperation with Africa to address migration issues    Allianz Egypt partners with IGNITE to equip brand ambassadors for 2021 Olympics    2021 International Women's Day highlights transformative power of equal participation: UN    Hassan Allam consortium wins contract to manage, operate Grand Egyptian Museum    Train derails killing 1, injuring 40 in southern Pakistan    Saudi-led coalition destroys eight Houthi drones: Saudi TV    Egypt condemns latest terror atack in Somalia    Sisi approves amending law honoring martyrs, victims, missing, injured in terror attacks    Live score: Liverpool v Fulham (English Premier League)    Pope visits Iraq's war-ravaged north on last day of tour    Messi provides 2 assists for Barca ahead of Madrid derby    Egypt detects 588 new coronavirus cases, 38 deaths on Saturday    Nigeria's Iheanacho, Ghana's Amartey give Leicester win over Brighton    Al-Sisi, Al-Burhan to intensify efforts towards reaching legally binding GERD agreement    Egypt's Aswan Forum for Sustainable Peace and Development II closed successfully: Foreign ministry    World Bank approves $440 million for enhancing Egypt's railways    Al-Sisi visits Sudan for first time after formation of new transitional government    Egypt stresses necessity of launching 'serious' negotiation process to reach deal on GERD before flood season    Egypt clubs protest Football Association decision to cover costs of COVID-19 tests    Messi serves as bright spot in Barcelona's disastrous season    Zamalek ready with striking force against Esperance Tunis    Sudan keen to enhance cooperation with Egypt: Sudanese FM Al-Mahdi    Egypt court upholds 3-year prison sentence for Mubarak-era Minister El-Feky    A Happy Purrfect Rescue Story of 4 Cats in Thailand    Egypt's Zamalek arrive in Tunisia to face Esperance in CAF Champions League    Winston Churchill's Moroccan landscape painting owned by Angelina Jolie sells for $11.5M    Orascom Construction to build Magdi Yacoub Global Heart Centre    Respect for diversity    Huawei launches HUAWEI FreeLace Pro in Egypt with extra-long battery life and top-grade noise cancellation    Enhanced Labs signs Mr. Olympia 2020 "Big Ramy" And His Trainer Dennis James    King Tutankhamun funerary mask is must-see tourist icon: The Telegraph    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    Egypt, Ethiopia, Sudan to resume Nile dam talks today    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Pfizer, BioNTech say their COVID-19 vaccine is more than 90% effective
Published in Ahram Online on 09 - 11 - 2020

Pfizer Inc on Monday said its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against a pandemic that has killed over 1 million people, roiled the world's economy and upended daily life.
Pfizer and German partner BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek U.S. emergency use authorization later this month.
If authorized, the number of vaccine doses will initially be limited. Many questions also remain including how long the vaccine will provide protection. However the news provides hope that other vaccines in development against the novel coronavirus may also prove effective.
"Today is a great day for science and humanity," Albert Bourla, Pfizer's chairman and chief executive, said in a statement. "We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen."
Pfizer expects to seek broad U.S. emergency use authorization of the vaccine for people aged 16 to 85. To do so, it will need to have collected two months of safety data on around half of the study's roughly 44,000 participants, expected in late November.
"I'm near ecstatic," Bill Gruber, one of Pfizer's top vaccine scientists, said in an interview. "This is a great day for public health and for the potential to get us all out of the circumstances we're now in."
Pfizer said the interim analysis was conducted after 94 participants in the trial developed COVID-19, examining how many of them received the vaccine versus a placebo.
The company did not break down exactly how many of those who fell ill received the vaccine. Still, over 90% effectiveness implies that no more than 8 of the 94 people who caught COVID-19 had been given the vaccine, which was administered in two shots about three weeks apart.
The efficacy rate is well above the 50% effectiveness required by the U.S. Food and Drug Administration for a coronavirus vaccine.
To confirm its efficacy rate, Pfizer said it will continue the trial until there are 164 COVID-19 cases among participants. Given the recent spike in U.S. infection rates, that number could be reached by early December, Gruber said.
The data have yet to be peer-reviewed or published in a medical journal. Pfizer said it would do so once it has results from the entire trial.
Pfizer and BioNTech have a $1.95 billion contract with the U.S. government to deliver 100 million vaccine doses beginning this year. They have also reached supply agreements with the European Union, the UK, Canada and Japan.
To save time, the companies began manufacturing the vaccine before they knew whether it would be effective. They now expect to produce up to 50 million doses or enough vaccine to protect 25 million people this year.
Pfizer said it expects to produce up to 1.3 billion doses of the vaccine in 2021.
GLOBAL RACE
The global race for a vaccine has seen wealthier countries forge multibillion-dollar supply deals with drugmakers like Pfizer, AstraZeneca Plc and Johnson & Johnson Inc , raising questions over when middle income and poorer nations will get access to inoculations.
The U.S. quest for a vaccine has been the Trump administration's central response to the pandemic. The United States has the world's highest known number of COVID-19 cases and deaths with more than 10 million infections and more than 237,000 fatalities.
President Donald Trump repeatedly assured the public that his administration would likely identify a successful vaccine in time for the presidential election, held last Tuesday. On Saturday, Democratic rival Joe Biden was declared the winner.
Vaccines are seen as essential tools to help end the health crisis that has shuttered businesses and left millions out of work. Millions of children whose schools were closed in March remain in remote learning programs.
Dozens of drugmakers and research groups around the globe have been racing to develop vaccines against COVID-19, which on Sunday exceeded 50 million infections since the novel coronavirus first emerged late last year in China.
The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines.
Moderna Inc, whose vaccine candidate employs similar technology, is expected to report results from its large-scale trial later this month. The mRNA technology is designed to trigger an immune response without using pathogens, such as actual virus particles.
Pfizer alone will not have the capacity to immediately provide enough vaccines for the entire United States. The Trump administration has said it will have enough supply for all of the 330 million U.S. residents who wish to be vaccinated by the middle of 2021.
The U.S. government has said the vaccines will be provided for free to Americans, including the insured, uninsured and those in government health programs such as Medicare.


Clic here to read the story from its source.